ArticleDiabetes therapy : research, treatment and education of diabetes and related disorders2026
Glycemic Patterns Assessed by Continuous Glucose Monitoring in People with Type 2 Diabetes Treated with Insulin Glargine 100 U/mL in Primary Care: The GPDetect Study.
Article in Diabetes therapy : research, treatment and education of diabetes and related disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionHypoglycemia is a common complication in people with type 2 diabetes mellitus (T2DM) treated with basal insulin, yet its true prevalence in real-world primary care remains underexplored. This study used blinded continuous glucose monitoring (CGM) to assess glycemic patterns in patients with T2DM on basal insulin-supported oral therapy (BOT) with insulin glargine 100 U/mL (Gla-100) in Spain.
methodsGPDetect was a prospective, multicenter, observational study in adults with T2DM treated with Gla-100 for ≥ 6 months in primary care. Participants underwent 14 days of blinded CGM (FreeStyle Libre
resultsAmong 136 patients (mean age 69 years), 16.9% had TBR > 4%, with a higher prevalence at night (23.5%) than during the day (12.5%). Clinically significant hypoglycemia (< 54 mg/dL > 1%) occurred in 8.8% of patients. Hyperglycemia was common: 46.3% spent > 25% of the day between 181-250 mg/dL, and 28.7% spent time > 250 mg/dL. Only 55.9% achieved TIR ≥ 70%. Patients receiving SGLT2i had lower mean glucose and EsHFS scores. Cognitive impairment (MMSE < 23) was associated with longer hypoglycemia duration.
conclusionsBlinded CGM revealed a relevant burden of unrecognized hypoglycemia-particularly nocturnal-as well as daytime hyperglycemia in patients with T2DM treated with Gla-100 in primary care. These results support the clinical value of CGM in informing treatment decisions and improving individualized diabetes management.
Indexed as
Identifiers
42554785What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.